Search research articles
Contact Us
Filters
Showing results (31-40 of 215) with videos related to
Page
of 22
Sort By:
Oncotarget
|
April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
Timothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood Advances
|
January 18, 2019
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
Daniel J Landsburg, Mitchell E Hughes, Alexa Koike, et al.
Leukemia
|
July 25, 2020
Second cancer incidence in CLL patients receiving BTK inhibitors
David A Bond, Ying Huang, James L Fisher, et al.
Leukemia
|
January 22, 2014
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
K A Beckwith, F W Frissora, M R Stefanovski, et al.
Blood
|
August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Leukemia & Lymphoma
|
February 12, 2015
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma
Farrukh T Awan, Joseph M Flynn, Jeffrey A Jones, et al.
Cochlear Implants International
|
December 25, 2016
United Kingdom national paediatric bilateral project: Demographics and results of localization and speech perception testing
H E Cullington, D Bele, J C Brinton, et al.
Leukemia
|
April 6, 2021
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients
Cecelia R Miller, Ying Huang, Amy S Ruppert, et al.
Cochlear Implants International
|
January 19, 2017
United Kingdom national paediatric bilateral project: Results of professional rating scales and parent questionnaires
H E Cullington, D Bele, J C Brinton, et al.
Cancer
|
March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
Jonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Page
of 22
Search research articles
Search
Showing results (31-40 of 215) with videos related to
Sort By:
Page
of 22
Oncotarget
|
April 24, 2016
Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
Timothy L Chen, Nikhil Gupta, Amy Lehman, et al.
Blood Advances
|
January 18, 2019
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
Daniel J Landsburg, Mitchell E Hughes, Alexa Koike, et al.
Leukemia
|
July 25, 2020
Second cancer incidence in CLL patients receiving BTK inhibitors
David A Bond, Ying Huang, James L Fisher, et al.
Leukemia
|
January 22, 2014
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
K A Beckwith, F W Frissora, M R Stefanovski, et al.
Blood
|
August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia
Kerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Leukemia & Lymphoma
|
February 12, 2015
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma
Farrukh T Awan, Joseph M Flynn, Jeffrey A Jones, et al.
Cochlear Implants International
|
December 25, 2016
United Kingdom national paediatric bilateral project: Demographics and results of localization and speech perception testing
H E Cullington, D Bele, J C Brinton, et al.
Leukemia
|
April 6, 2021
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients
Cecelia R Miller, Ying Huang, Amy S Ruppert, et al.
Cochlear Implants International
|
January 19, 2017
United Kingdom national paediatric bilateral project: Results of professional rating scales and parent questionnaires
H E Cullington, D Bele, J C Brinton, et al.
Cancer
|
March 1, 2014
Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival
Jonathon B Cohen, Susan M Geyer, Gerard Lozanski, et al.
Page
of 22